The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells
Juan Carlos López-Gil,Susana García-Silva,Laura Ruiz-Cañas,Diego Navarro,Adrián Palencia-Campos,Antonio Giráldez-Trujillo,Julie Earl,Jorge Dorado,Gonzalo Gómez-López,Ana Monfort-Vengut,Sonia Alcalá,Matthias M Gaida,Sandra García-Mulero,Pablo Cabezas-Sáinz,Sandra Batres-Ramos,Emma Barreto,Patricia Sánchez-Tomero,Mireia Vallespinós,Leah Ambler,Meng-Lay Lin,Alexandra Aicher,Ana García García de Paredes,Carolina de la Pinta,Alfonso Sanjuanbenito,Ignacio Ruz-Caracuel,Mercedes Rodríguez-Garrote,Carmen Guerra,Alfredo Carrato,Guillermo de Cárcer,Laura Sánchez,César Nombela-Arrieta,Elisa Espinet,Víctor Javier Sanchez-Arevalo Lobo,Christopher Heeschen,Bruno Sainz Jr
DOI: https://doi.org/10.1136/gutjnl-2023-330995
IF: 24.5
2024-08-08
Gut
Abstract:Objective: Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options, particularly with immune checkpoint inhibitors. Highly chemoresistant 'stem-like' cells, known as cancer stem cells (CSCs), are implicated in PDAC aggressiveness. Thus, comprehending how this subset of cells evades the immune system is crucial for advancing novel therapies. Design: We used the KPC mouse model (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) and primary tumour cell lines to investigate putative CSC populations. Transcriptomic analyses were conducted to pinpoint new genes involved in immune evasion. Overexpressing and knockout cell lines were established with lentiviral vectors. Subsequent in vitro coculture assays, in vivo mouse and zebrafish tumorigenesis studies, and in silico database approaches were performed. Results: Using the KPC mouse model, we functionally confirmed a population of cells marked by EpCAM, Sca-1 and CD133 as authentic CSCs and investigated their transcriptional profile. Immune evasion signatures/genes, notably the gene peptidoglycan recognition protein 1 (PGLYRP1), were significantly overexpressed in these CSCs. Modulating PGLYRP1 impacted CSC immune evasion, affecting their resistance to macrophage-mediated and T-cell-mediated killing and their tumourigenesis in immunocompetent mice. Mechanistically, tumour necrosis factor alpha (TNFα)-regulated PGLYRP1 expression interferes with the immune tumour microenvironment (TME) landscape, promoting myeloid cell-derived immunosuppression and activated T-cell death. Importantly, these findings were not only replicated in human models, but clinically, secreted PGLYRP1 levels were significantly elevated in patients with PDAC. Conclusions: This study establishes PGLYRP1 as a novel CSC-associated marker crucial for immune evasion, particularly against macrophage phagocytosis and T-cell killing, presenting it as a promising target for PDAC immunotherapy.